Gossamer Bio (NASDAQ:GOSS) Stock Rated Buy in New Coverage at Chardan Capital

Chardan Capital began coverage on shares of Gossamer Bio (NASDAQ:GOSS) in a report issued on Tuesday, Marketbeat Ratings reports. The brokerage set a “buy” rating on the stock.

A number of other analysts have also weighed in on the company. Leerink Partners raised Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 price objective for the company in a research note on Tuesday, July 28th. Wall Street Zen cut shares of Gossamer Bio from a “hold” rating to a “sell” rating in a research note on Sunday, September 20th. Weiss Ratings upgraded shares of Gossamer Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Gossamer Bio in a research report on Thursday, August 27th. Five analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $256.00.

Gossamer Bio Trading Up 5.7%

Gossamer Bio stock traded up $0.53 during midday trading on Tuesday, reaching $9.81. The stock had a trading volume of 293,666 shares, compared to its average volume of 241,391. Gossamer Bio has a 12 month low of $8.99 and a 12 month high of $309.60. The company has a fifty day moving average price of $12.34 and a two-hundred day moving average price of $17.38. The company has a market capitalization of $59.94 million, a P/E ratio of -0.18 and a beta of 2.21.

Hedge Funds Weigh In On Gossamer Bio

Several large investors have recently added to or reduced their stakes in GOSS. ADAR1 Capital Management LLC acquired a new position in Gossamer Bio during the second quarter worth about $35,000. Hsbc Holdings PLC bought a new stake in Gossamer Bio during the first quarter worth approximately $38,000. SG Americas Securities LLC increased its position in Gossamer Bio by 73.4% during the first quarter. SG Americas Securities LLC now owns 128,568 shares of the company’s stock worth $42,000 after acquiring an additional 54,439 shares during the period. Bank of America Corp DE acquired a new stake in Gossamer Bio in the 2nd quarter valued at $65,000. Finally, Ieq Capital LLC acquired a new stake in Gossamer Bio during the 2nd quarter valued at $97,000. 81.23% of the stock is currently owned by hedge funds and other institutional investors.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with disorders involving the immune system, inflammation and fibrosis. The company is headquartered in San Diego, California, and primarily operates through the development of its proprietary drug candidates and strategic collaborations.

Gossamer’s lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways associated with pulmonary vascular remodeling.